| Name | Title | Contact Details |
|---|
The New York Jets are a professional football team headquartered in Florham Park, New Jersey, representing the New York metropolitan area. It is a privately owned business with under 200 employees. Founded more than 50 years ago, the Jets franchise has defined itself as a trailblazer, trendsetter and leader in the regions sports landscape and across the NFL. Since Chairman and CEO Woody Johnson purchased the team in 2000, the team has undergone a major revitalization and rebranding, focused on winning both on and off the field. For Johnson, capturing the franchises second championship is priority #1. Under his ownership, the team has posted seven winning seasons, appeared in seven postseason games, including two AFC Championship Game appearances, and winning an AFC East division title in 2002. They have also made strides off the field with the opening of two state-of-the-art homes: the Atlantic Health Jets Training Center in 2008 and MetLife Stadium in 2010. Honored as one of NJ Bizs 2018 Best Places to Work in New Jersey. This award recognizes and honors New Jersey-based employers who show dedication to their employees professional growth and quality of life.
Geofabrica is a manufacturing technology development company specializing in customized additive manufacturing systems for factory and expeditionary applications. We build innovative solutions to unlock the economic and production potential of 3D printing and additive technologies for metal, plastic, and composite applications. We create application-specific devices and processes to help customers overcome the limitations of current technologies and help them achieve a competitive advantage within the evolving digital manufacturing landscape. ITAR registered, JCP certified, NIST 800-171 compliant.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Net Zero Since Day Zero. The ABB FIA Formula E World Championship brings dramatic racing to the heart of some of the worlds most iconic cities providing an elite motorsport platform for the worlds leading automotive manufacturers to accelerate electric vehicle innovation. The Formula E network of teams, manufacturers, partners, broadcasters, and host cities are united by a passion for the sport and belief in its potential to accelerate sustainable human progress and create a better future for people and planet.